Market Research Logo

Global Kidney Cancer Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Kidney Cancer Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

The global kidney cancer drug market is estimated to reach by USD 4.5 billion at a CAGR of 6.2% till 2022. Growing prevalence for lifestyle tempted diseases such as excessive drinking and smoking coupled with chronic diseases such as kidney cancer and tumor are some of the driving factors which are responsible for the growth of the market of kidney cancer drug. Increasing geriatric population is also contributing for the growth of the market as the people of this age group are more likely to suffer by chronic diseases. Additionally, these cancer drugs are long term treatment regiments which are available for patients who are at stage advanced metastatic tumor. Along with the driving factors the kidney cancer drug market also has the factors which are responsible for hampering the market growth such as increasing preference for geriatric drug among the consumers and high prices for branded drugs are some of the restraints which are negatively impacting the market growth of kidney cancer drug.

The global kidney cancer drug market is majorly segmented on the basis of type, on the basis of brand and on the basis of geography. Based upon the type the kidney cancer drug market is categorized in to clear cell, papillary (type 1 and type 2), chromophobe, oncocytic, and collecting duct. Based upon the brand the kidney cancer drug market is sub categorized in to nexavar (sorafenib), sutent (sunitinib), afinitor (Everolimus), votrient (pazopanib) , Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), and Proleukin (Aldesleukin).

Sutent (sunitinib) is a well-known cancer drug and more often used as the first line treatment of renal cell carcinoma (RCC) but due to the relatively high pricing of sunitinib drug has been proven a serious drawback for the use of sutent drug although it has been considered as the first line agent for the treatment for renal cell carcinoma (RCC). In terms of market growth the drug, votrient is estimated to have the highest growth rate among the entire kidney cancer drug during the coming years.

On the basis of the geography the kidney cancer drug market is mainly segmented into North America, Latin America, Europe, APAC and the rest of the world. North America holds the largest market share for kidney cancer drug globally. Rising prevalence of kidney cancer and kidney diseases are majorly impacting the marker growth in this region.

However, during the forecasted years Asia Pacific region is also expected to see the highest growth due to the rising patient awareness level and lower cost production of drugs and increase in patients who are suffering from renal diseases such as kidney cell carcinoma.

The kidney cancer drug market is dominated by some of the major key players such asF. Hoffmann-La Roche AG (Switzerland), Amgen (US),Onyx Pharmaceuticals Inc. (US), Bayer AG (Germany), Active Biotech AB (Sweden),GlaxoSmithKline plc (UK), Novartis AG (Switzerland) Genentech, Inc. (US), Cipla Limited (India), these are the key player who dominate the world market with 50% share of global kidney cancer drug market.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.3. PARAMETRIC ANALYSIS
2.4. KEY MARKET INSIGHTS
2.4.1. TOP EMERGING COUNTRIES
2.4.2. TOP REVENUE GENERATING SEGMENTS
2.4.3. EMERGING TRENDS
2.5. COMPETITIVE LANDSCAPE
2.5.1. MARKET SHARE ANALYSIS
2.5.2. TOP WINNING STRATEGIES
2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
2.6. PORTER’S FIVE FORCE MODEL
2.6.1. THREAT OF NEW ENTRANTS
2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
2.6.3. BARGAINING POWER OF BUYER
2.6.4. BARGAINING POWER OF SUPPLIER
2.6.5. INTENSITY OF COMPETITIVE RIVALRY
2.7. KEY BUYING CRITERIA
2.8. STRATEGIC RECOMMENDATION
2.9. STRATEGIC CONCLUSIONS
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING INCIDENCES FOR KIDNEY CANCERS
3.1.2. GROWING GERIATRIC POPULATION
3.2. MARKET RESTRAINTS
3.2.1. INCREASING PREFERENCE FOR GERIATRIC DRUGS
3.3. MARKET OPPORTUNITIES
3.3.1. APPROVAL OF NOVEL MOLECULES FOR DEVELOPMENT OF DRUGS
3.3.2. INCREASE IN R&D
3.4. MARKET CHALLENGES
3.4.1. HIGH PRICES OF BRANDED DRUGS
3.5. PARENT MARKET
3.6. COMPETITORS MARKET
3.7. ALTERNATIVE MARKET
4. MARKET SEGMENTATION
4.1. GLOBAL KIDNEY CANCER DRUG BY TYPE 2014-2022($MILLION)
4.1.1. GLOBAL CLEAR CELL MARKET 2014-2022 ($MILLION)
4.1.2. GLOBAL PAPILLARY MARKET 2014-2022 ($MILLION)
4.1.3. GLOBAL CHROMOPHOBE MARKET 2014-2022 ($MILLION)
4.1.4. GLOBAL ONCOCYTIC MARKET 2014-2022 ($MILLION)
4.1.5. GLOBAL COLLECTING DUCT MARKET 2014-2022 ($MILLION)
4.2. GLOBAL KIDNEY CANCER DRUG BY BRAND MARKET 2014-2022 ($MILLION)
4.2.1. GLOBAL NEXAVAR (SORAFENIB)MARKET 2014-2022 ($MILLION)
4.2.2. GLOBAL SUTENT (SUNITINIB) MARKET 2014-2022 ($MILLION)
4.2.3. GLOBAL AFINITOR (EVEROLIMUS) MARKET 2014-2022 ($MILLION)
4.2.4. GLOBAL VOTRIENT (PAZOPANIB) MARKET 2014-2022 ($MILLION)
4.2.5. GLOBAL AVASTIN (BEVACIZUMAB) MARKET 2014-2022 ($MILLION)
4.2.6. GLOBAL INLYTA (AXITINIB) MARKET 2014-2022 ($MILLION)
4.2.7. GLOBAL TORISEL (TEMSIROLIMUS) MARKET 2014-2022 ($MILLION)
4.2.8. GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET 2014-2022 ($MILLION)
5. GEOGRAPHIC ANALYSIS
5.1. NORTH AMERICA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.1.1. UNITED STATES (U.S.) KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.1.2. CANADA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2. EUROPE KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.1. UNITED KINGDOM (UK) KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.2. FRANCE KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.3. GERMANY KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.4. SPAIN KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.5. ITALY KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.2.6. ROE KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.3. ASIA PACIFIC KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.3.1. INDIA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.3.2. CHINA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.3.3. JAPAN KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.3.4. ROAPAC KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.4. REST OF THE WORLD KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.4.1. LATIN AMERICA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.4.2. MENA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
5.4.3. AFRICA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
6. COMPANY PROFILE: - (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)
ACTIVE BIOTECH AB (SWEDEN),
AMGEN (US),
BAYER AG (GERMANY),
CIPLA LIMITED (INDIA),
F. HOFFMANN-LA ROCHE AG (SWITZERLAND),
GENENTECH, INC. (US),
GLAXOSMITHKLINE PLC (UK),
NOVARTIS AG (SWITZERLAND),
ONYX PHARMACEUTICALS INC. (US),
PFIZER, INC. (US)
ABBOTT LABORATORIES
AVEO PHARMACEUTICALS
IMMATICS BIOTECHNOLOGIES
PROMETHEUS LABORATORIES
EXELIXIS
LIST OF TABLES
GLOBAL KIDNEY CANCER DRUG BY TYPE 2014-2022 ($MILLION)
GLOBAL CLEAR CELL MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL PAPILLARY MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL CHROMOPHOBE MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL ONCOCYTIC MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL COLLECTING DUCT MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL KIDNEY CANCER DRUG BY BRAND MARKET 2014-202 ($MILLION)
GLOBAL NEXAVAR (SORAFENIB) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL SUTENT (SUNITINIB) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL AFINITOR (EVEROLIMUS) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL VOTRIENT (PAZOPANIB) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL AVASTIN (BEVACIZUMAB) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL INLYTA (AXITINIB) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL TORISEL (TEMSIROLIMUS) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET BY GEOGRAPHY 2014-2022 ($MILLION)
NORTH AMERICA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
EUROPE KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
ASIA PACIFIC KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
REST OF THE WORLD KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
LIST OF FIGURES
GLOBAL CLEAR CELL MARKET 2014-2022 ($MILLION)
GLOBAL PAPILLARY MARKET 2014-2022 ($MILLION)
GLOBAL CHROMOPHOBE MARKET 2014-2022 ($MILLION)
GLOBAL ONCOCYTIC MARKET 2014-2022 ($MILLION)
GLOBAL COLLECTING DUCT MARKET 2014-2022 ($MILLION)
GLOBAL NEXAVAR (SORAFENIB) MARKET 2014-2022 ($MILLION)
GLOBAL SUTENT (SUNITINIB) MARKET 2014-2022 ($MILLION)
GLOBAL AFINITOR (EVEROLIMUS) MARKET 2014-2022 ($MILLION)
GLOBAL VOTRIENT (PAZOPANIB) MARKET 2014-2022 ($MILLION)
GLOBAL AVASTIN (BEVACIZUMAB) MARKET 2014-2022 ($MILLION)
GLOBAL INLYTA (AXITINIB) MARKET 2014-2022 ($MILLION)
GLOBAL TORISEL (TEMSIROLIMUS) MARKET 2014-2022 ($MILLION)
GLOBAL PROLEUKIN (ALDESLEUKIN) MARKET 2014-2022 ($MILLION)
NORTH AMERICA KIDNEY CANCER DRUG MARKET, 2014-2022 ($MILLION)
UNITED STATES (US) KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
CANADA KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
EUROPE KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
UNITED KINGDOM (UK) KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION)
FRANCE KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
GERMANY KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
SPAIN KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
ITALY KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
ROE KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
ASIA PACIFIC KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
INDIA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
CHINA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
JAPAN KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
KOREA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
AUSTRALIA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
ROAPAC KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
REST OF THE WORLD KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
LATIN AMERICA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
MENA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)
AFRICA KIDNEY CANCER DRUG MARKET, 2014-2022, ($MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report